Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Inclusion Criteria: 1. 18-75 years of age. 2. ECOG performance status: level 0\~1; 3. Anticipated life expectancy ≥ 12 weeks; 4. Lung cancer patients; 5. Major organs in good function; 6. Agree to take approved method of contraception during the clinical trail and 8 weeks after the last dose of apatinib. Female subject should be negative in the pregnancy test; 7. Able to comprehend and willing to sign an informed consent form (ICF) Exclusion Criteria: 1. History of drug allergy, or allergic to apatinib or gefitinib or ingredients; 2. Squamous cancer, small-cell lung cancer; 3. Symptomatic central nervous system (CNS) metastases 4. Hypertension and couldn't be controlled with medicine; 5. Coagulation disorders; 6. Clinical significant bleeding in 3 months prior dosing; 7. Had surgery in four weeks prior dosing; 8. Disease that affect drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction; 9. Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess in 6 months prior dosing; 10. Urine protein ≥++, and urine protein ≥1.0g in 24 hours; 11. Active infection and need antimicrobial treatments; 12. History of psychiatric substance abuse; 13. Take any clinical trial drugs within four weeks prior dosing; 14. Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A and CYP2D6; 15. Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or combined with syphilis infection; 16. Addicted to alcohol and tobacco; 17. Take grapefruit or grapefruit product, drinks containing caffeine, xanthine and alcohol in 48 hours prior dosing; 18. The investigator believes that the subjects are not eligible to participate in this trial.